KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Liabilities from Discontinued Operations (2021 - 2026)

TherapeuticsMD filings provide 7 years of Liabilities from Discontinued Operations readings, the most recent being 2667000.0 for Q1 2026.

  • On a quarterly basis, Liabilities from Discontinued Operations fell 4.24% to 2667000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was 2667000.0, a 4.24% decrease, with the full-year FY2025 number at 2667000.0, down 4.1% from a year prior.
  • Liabilities from Discontinued Operations hit 2667000.0 in Q1 2026 for TherapeuticsMD, roughly flat from 2667000.0 in the prior quarter.
  • In the past five years, Liabilities from Discontinued Operations ranged from a high of 25831000.0 in Q4 2022 to a low of 1372000.0 in Q2 2023.
  • Median Liabilities from Discontinued Operations over the past 5 years was 2783000.0 (2024), compared with a mean of 4925928.57.
  • Biggest five-year swings in Liabilities from Discontinued Operations: plummeted 85.7% in 2023 and later surged 138.45% in 2024.
  • TherapeuticsMD's Liabilities from Discontinued Operations stood at 25831000.0 in 2022, then plummeted by 85.7% to 3694000.0 in 2023, then dropped by 24.72% to 2781000.0 in 2024, then dropped by 4.1% to 2667000.0 in 2025, then changed by 0.0% to 2667000.0 in 2026.
  • The last three reported values for Liabilities from Discontinued Operations were 2667000.0 (Q1 2026), 2667000.0 (Q4 2025), and 2667000.0 (Q3 2025) per Business Quant data.